105 related articles for article (PubMed ID: 25897103)
1. Serum β-glucuronidase as a potential colon cancer marker: a preliminary study.
Waszkiewicz N; Szajda SD; Konarzewska-Duchnowska E; Zalewska-Szajda B; Gałązkowski R; Sawko A; Nammous H; Buko V; Szulc A; Zwierz K; Ładny JR
Postepy Hig Med Dosw (Online); 2015 Apr; 69():436-9. PubMed ID: 25897103
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin D and carcino-embryonic antigen in serum, urine and tissues of colon adenocarcinoma patients.
Szajda SD; Snarska J; Jankowska A; Roszkowska-Jakimiec W; Puchalski Z; Zwierz K
Hepatogastroenterology; 2008; 55(82-83):388-93. PubMed ID: 18613372
[TBL] [Abstract][Full Text] [Related]
3. Lysosomal exoglycosidases in serum and urine of patients with colon adenocarcinoma.
Szajda SD; Snarska J; Puchalski Z; Zwierz K
Hepatogastroenterology; 2008; 55(84):921-5. PubMed ID: 18705298
[TBL] [Abstract][Full Text] [Related]
4. Activin A as a novel biomarker for colorectal adenocarcinoma in humans.
Wu S; Qi Y; Niu LM; Xie DX; Cui XL; Liu ZH
Eur Rev Med Pharmacol Sci; 2015 Nov; 19(22):4371-8. PubMed ID: 26636525
[TBL] [Abstract][Full Text] [Related]
5. The role of neurotensin as a novel biomarker in the endoscopic screening of high-risk population for developing colorectal neoplasia.
Kontovounisios C; Qiu S; Rasheed S; Darzi A; Tekkis P
Updates Surg; 2017 Sep; 69(3):397-402. PubMed ID: 28560510
[TBL] [Abstract][Full Text] [Related]
6. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer.
Knychalski B; Lukieńczuk T
Pol Przegl Chir; 2012 Feb; 84(2):86-92. PubMed ID: 22487741
[TBL] [Abstract][Full Text] [Related]
7. Low-serum GTA-446 anti-inflammatory fatty acid levels as a new risk factor for colon cancer.
Ritchie SA; Tonita J; Alvi R; Lehotay D; Elshoni H; Myat S; McHattie J; Goodenowe DB
Int J Cancer; 2013 Jan; 132(2):355-62. PubMed ID: 22696299
[TBL] [Abstract][Full Text] [Related]
8. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers.
Leman ES; Schoen RE; Weissfeld JL; Cannon GW; Sokoll LJ; Chan DW; Getzenberg RH
Cancer Res; 2007 Jun; 67(12):5600-5. PubMed ID: 17575123
[TBL] [Abstract][Full Text] [Related]
9. N-acetyl-beta-D-hexosaminidase and its isoenzymes A and B in blood serum and urine, as a potential colon cancer markers.
Szajda SD; Borzym-Kluczyk M; Snarska J; Puchalski Z; Zwierz K
Hepatogastroenterology; 2009; 56(94-95):1287-98. PubMed ID: 19950779
[TBL] [Abstract][Full Text] [Related]
10. Raised prostate-specific antigen in adenocarcinoma of the colon.
Yamamoto M; Hibi H; Miyake K
Int Urol Nephrol; 1997; 29(2):221-5. PubMed ID: 9241551
[TBL] [Abstract][Full Text] [Related]
11. A study of serum glycosidases in cancer.
Severini G; Diana L; Di Giovannandrea R; Tirelli C
J Cancer Res Clin Oncol; 1995; 121(1):61-3. PubMed ID: 7860621
[TBL] [Abstract][Full Text] [Related]
12. Expression of interleukine-8 as an independent prognostic factor for sporadic colon cancer dissemination.
Nastase A; Paslaru L; Herlea V; Ionescu M; Tomescu D; Bacalbasa N; Dima S; Popescu I
J Med Life; 2014 Jun; 7(2):215-9. PubMed ID: 25408728
[TBL] [Abstract][Full Text] [Related]
13. An enzyme-activated two-photon ratiometric fluorescent probe with lysosome targetability for imaging β-glucuronidase in colon cancer cells and tissue.
Wei X; Li J; Yang X; Dong B; Geng B; Li Z; Hu X; Ding B; Zhang J; Yan M
Anal Chim Acta; 2022 Feb; 1192():339354. PubMed ID: 35057945
[TBL] [Abstract][Full Text] [Related]
14. The activity of serum beta-galactosidase in colon cancer patients with a history of alcohol and nicotine dependence: preliminary data.
Waszkiewicz N; Szajda SD; Waszkiewicz M; Wojtulewska-Supron A; Szulc A; Kępka A; Chojnowska S; Dadan J; Ładny JR; Zwierz K; Zalewska-Szajda B
Postepy Hig Med Dosw (Online); 2013 Aug; 67():896-900. PubMed ID: 24018455
[TBL] [Abstract][Full Text] [Related]
15. Serum Levels of TRIM72 Are Lower among Patients with Colon Cancer: Identification of a Potential Diagnostic Marker.
Chen Z; Yin X; Li K; Chen S; Li H; Li Y; Zhang Q; Wang H; Qiu Y
Tohoku J Exp Med; 2018 May; 245(1):61-68. PubMed ID: 29806630
[TBL] [Abstract][Full Text] [Related]
16. Galanin is up-regulated in colon adenocarcinoma.
Kim KY; Kee MK; Chong SA; Nam MJ
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2373-8. PubMed ID: 18006926
[TBL] [Abstract][Full Text] [Related]
17. Activins and their related proteins in colon carcinogenesis: insights from early and advanced azoxymethane rat models of colon cancer.
Refaat B; El-Shemi AG; Mohamed AM; Kensara OA; Ahmad J; Idris S
BMC Cancer; 2016 Nov; 16(1):879. PubMed ID: 27835986
[TBL] [Abstract][Full Text] [Related]
18. Serum MMP7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients.
Klupp F; Neumann L; Kahlert C; Diers J; Halama N; Franz C; Schmidt T; Koch M; Weitz J; Schneider M; Ulrich A
BMC Cancer; 2016 Jul; 16():494. PubMed ID: 27431388
[TBL] [Abstract][Full Text] [Related]
19. Modulation of natural killer cell activity by serum from cancer patients: preliminary results of a study of patients with colorectal adenocarcinoma or other types of cancer.
Pislarasu M; Oproiu A; Taranu D; Herberman RB; Sulica A
Cancer Res; 1988 May; 48(9):2596-603. PubMed ID: 3356020
[TBL] [Abstract][Full Text] [Related]
20. Activity of alpha-fucosidase and beta-glucuronidase in serum and urine of patients administered parenteral nutrition.
Raczkowska K; Szajda SD; Raczkowski K; Zasadowska W; Chojnowska S; Kepka A; Zalewska-Szajda B; Waszkiewicz N; Knaś M; Snarska J; Zwierz K; Ladny JR
Rocz Panstw Zakl Hig; 2013; 64(3):235-41. PubMed ID: 24325091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
